Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Radiotherapy Combined With Nitozumab and Sinilimab in the Treatment of Locally Advanced Unresectable Platinum Intolerant Head and Neck Squamous Cell Carcinoma： an Open-label Single-arm, Phase II Trial

NCT05831930 is registered in ClinicalTrials.gov with Sichuan Cancer Hospital and Research Institute as lead sponsor.

NCT NCT05831930
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05831930 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Radiotherapy Combined With Nitozumab and Sinilimab in the Treatment of Locally Advanced Unresectable Platinum Intolerant Head and Neck Squamous Cell Carcinoma： an Open-label Single-arm, Phase II Trial
Lead sponsor
Sichuan Cancer Hospital and Research Institute
Phase
Phase 1
Overall status
Unknown status
Start date
January 17, 2023
Completion date
January 31, 2026
Enrollment
62 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hnscc